1998
Verapamil use in patients with cardiovascular disease: An overview of randomized trials
Pepine C, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: An overview of randomized trials. Clinical Cardiology 1998, 21: 633-641. PMID: 9755379, PMCID: PMC6655547, DOI: 10.1002/clc.4960210906.Peer-Reviewed Original ResearchConceptsMyocardial infarctionVerapamil useNonfatal reinfarctionCalcium antagonistsDecreased riskDrug classesCardiovascular diseaseCertain calcium antagonistsNonfatal myocardial infarctionOutcome of deathParallel-group studyStandard meta-analytic techniquesRandomized clinical trialsAcute myocardial infarctionEnglish-language articlesEvidence of harmAngina StudyHypertensive patientsOverall mortalityRandomized studyRandomized trialsTrial characteristicsClinical trialsPatient outcomesMEDLINE search
1996
Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas.
Piepmeier J, Susan Christopher R, Spencer D, Byrne T, Kim J, Knisel J, Lacy J, Tsukerman L, Makuch R. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996, 38: 872-8; discussion 878-9. PMID: 8727811, DOI: 10.1097/00006123-199605000-00002.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGross total resectionChronic epilepsySupratentorial low-grade astrocytomasNatural historyGross total tumor resectionImmediate postoperative radiotherapyExtent of surgerySurvival of patientsTen-year survivalPopulation of patientsUse of radiotherapyRisk of recurrenceHigh-grade lesionsLength of survivalMore malignant tumorsTypes of symptomsAggressive surgeryPostoperative radiotherapyPreoperative symptomsConsecutive patientsBetter prognosisTumor recurrenceTumor resectionMalignant tumors
1991
A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer
Murren J, Ganpule S, Sarris A, Durivage H, Davis C, Makuch R, Handschumacher R, Marsh J. A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer. American Journal Of Clinical Oncology 1991, 14: 208-217. PMID: 2031507, DOI: 10.1097/00000421-199106000-00007.Peer-Reviewed Original ResearchConceptsPhase II trialCyclosporin AII trialColorectal cancerEuropean Cooperative Oncology Group performance statusRefractory metastatic colorectal cancerSignificant toxicityRefractory colorectal cancerMetastatic colorectal cancerFlu-like symptomsMeasurable diseaseStable diseaseStarting doseColorectal malignancyObjective responsePerformance statusImmunosuppressive agentsInitial doseDose reductionColon cancerPatientsHuman neoplasmsExperimental modelCancerDoseHigh‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma
Murren J, Derosa W, Durivage H, Davis C, Makuch R, Portlock C. High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991, 67: 1514-1517. PMID: 2001539, DOI: 10.1002/1097-0142(19910315)67:6<1514::aid-cncr2820670609>3.0.co;2-q.Peer-Reviewed Original Researchmyc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens.
Brennan J, O'Connor T, Makuch R, Simmons A, Russell E, Linnoila R, Phelps R, Gazdar A, Ihde D, Johnson B. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Research 1991, 51: 1708-12. PMID: 1847842.Peer-Reviewed Original ResearchConceptsMyc family DNA amplificationSmall cell lung cancerCell lung cancerLung cancerTumor cell linesExtensive-stage small-cell lung cancer patientsSmall cell lung cancer patientsCell linesPatient specimensCell lung cancer patientsDNA copy numberDifferent combination chemotherapyEtoposide/cisplatinDifferent chemotherapy regimensInitiation of therapyLung cancer patientsFrequency of amplificationChemotherapy regimensUntreated patientsCombination chemotherapyCancer patientsSame patientPatientsClinical situationsDNA amplification
1989
Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 Infection
Scott G, Hutto C, Makuch R, Mastrucci M, O'Connor T, Mitchell C, Trapido E, Parks W. Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 Infection. New England Journal Of Medicine 1989, 321: 1791-1796. PMID: 2594038, DOI: 10.1056/nejm198912283212604.Peer-Reviewed Original ResearchConceptsMedian survivalMedian ageHuman immunodeficiency virus type 1 (HIV-1) infectionHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Common first manifestationLymphoid interstitial pneumoniaIntravenous drug useProportional hazards analysisTime of diagnosisPneumocystis carinii pneumoniaHIV-1 infectionMedian survival timeType 1 infectionRecurrent bacterial infectionsJackson Memorial HospitalLong-term survivalYears of ageVirus type 1Candida esophagitisProgressive diseaseAntiviral treatmentBlood transfusionInterstitial pneumonia